Haemonetics (NYSE:HAE) Price Target Lowered to $62.00 at JPMorgan Chase & Co.

Haemonetics (NYSE:HAE) had its price target cut by equities research analysts at JPMorgan Chase & Co. from $74.00 to $62.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a “neutral” rating on the medical instruments supplier’s stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 12.47% from the company’s current price.

Other analysts also recently issued research reports about the stock. BTIG Research reissued a “buy” rating and set a $88.00 target price on shares of Haemonetics in a research report on Friday, February 6th. Robert W. Baird set a $67.00 target price on shares of Haemonetics in a research report on Friday. Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. Barrington Research set a $94.00 target price on shares of Haemonetics in a research report on Friday, February 6th. Finally, Citigroup decreased their target price on shares of Haemonetics from $75.00 to $70.00 and set a “neutral” rating for the company in a research report on Wednesday, March 11th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $79.89.

Haemonetics Trading Up 1.4%

Shares of Haemonetics stock traded up $0.76 on Friday, hitting $55.13. The stock had a trading volume of 647,875 shares, compared to its average volume of 827,052. The stock has a 50 day moving average of $59.53 and a 200 day moving average of $66.68. Haemonetics has a twelve month low of $47.31 and a twelve month high of $87.32. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.15 and a current ratio of 1.75. The firm has a market capitalization of $2.56 billion, a P/E ratio of 15.19, a PEG ratio of 1.03 and a beta of 0.53.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.01. The business had revenue of $346.35 million during the quarter, compared to the consensus estimate of $336.83 million. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.24 EPS. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Sell-side analysts expect that Haemonetics will post 4.95 earnings per share for the current fiscal year.

Institutional Trading of Haemonetics

Large investors have recently modified their holdings of the stock. Federated Hermes Inc. grew its position in shares of Haemonetics by 1,405.7% during the 3rd quarter. Federated Hermes Inc. now owns 46,104 shares of the medical instruments supplier’s stock worth $2,247,000 after buying an additional 43,042 shares during the period. Isthmus Partners LLC lifted its holdings in shares of Haemonetics by 36.5% in the 3rd quarter. Isthmus Partners LLC now owns 61,702 shares of the medical instruments supplier’s stock worth $3,007,000 after purchasing an additional 16,505 shares in the last quarter. Invenomic Capital Management LP lifted its holdings in shares of Haemonetics by 1,691.5% in the 3rd quarter. Invenomic Capital Management LP now owns 498,317 shares of the medical instruments supplier’s stock worth $24,288,000 after purchasing an additional 470,502 shares in the last quarter. Skylands Capital LLC lifted its holdings in shares of Haemonetics by 195.4% in the 3rd quarter. Skylands Capital LLC now owns 81,369 shares of the medical instruments supplier’s stock worth $3,966,000 after purchasing an additional 53,819 shares in the last quarter. Finally, Barrow Hanley Mewhinney & Strauss LLC lifted its holdings in shares of Haemonetics by 16.5% in the 3rd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 559,972 shares of the medical instruments supplier’s stock worth $27,293,000 after purchasing an additional 79,138 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

More Haemonetics News

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Q4 results beat consensus: Haemonetics reported $1.29 EPS and $346.4M revenue (both ahead of Street estimates), with revenue up ~4.8% year-over-year — a core reason investors are bidding the stock up. Haemonetics (NYSE:HAE) Reports Upbeat Q1 CY2026
• Positive Sentiment: Management expects FY2027 revenue growth of 4%–7%, citing continued Persona PLUS rollout and efforts to rebound IVT volumes — these operational drivers support the growth narrative that investors are rewarding. Haemonetics projects FY 2027 revenue growth of 4% to 7%…
• Positive Sentiment: Outside buying signal: The London Company’s Small Cap Portfolio added to Haemonetics following recent volatility, indicating some institutional interest that can lift sentiment and trading. The London Company Small Cap Portfolio Q1 2026 Portfolio Review
• Neutral Sentiment: FY2027 EPS guidance band (5.258–5.307) is roughly in line with consensus (about 5.29), so while guidance supports stability, it doesn’t represent a clear upside surprise versus expectations. PR Newswire: Financial results available
• Neutral Sentiment: Investors can review the full earnings call transcript and supplemental materials for management commentary and cadence on Persona PLUS and IVT recovery; these details will shape whether the current upbeat reaction sustains. Haemonetics Q4 2026 Earnings Call Transcript

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.